CLOs on the Move

Dentalcorp

www.dentalcorp.ca

 
dentalcorp is Canada`s largest network of dental practices, committed to advancing the overall well-being of Canadians by aiming to deliver the best clinical outcomes and unforgettable experiences. dentalcorp acquires leading dental practices, uniting them in a common goal: to be Canada`s most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth. dentalcorp provides world-class resources to Partners including Talent & Recruitment, Human Resources, Training & Development, Legal & Compliance, Practice Optimization, Marketing, IT, Procurement, Finance, AP, and Payroll. We enable the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.dentalcorp.ca
  • 181 Bay Street Suite 2600
    Toronto, ON CAN M5J 2T3
  • Phone: 416.558.8338

Executives

Name Title Contact Details
Julian Perez
 Chief Legal Officer Profile

Similar Companies

Elona Biotechnologies

Elona Biotechnologies , Inc. is a Greenwood, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Airsys

Airsys is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Informatics Corporation of America

Informatics Corporation of America is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kerr Drug, Inc.

Kerr Drug recognizes that, for most of our customers, convenient access to products and services is a critical issue. That is why we go the extra mile to insure that our customers have the largest selection of things they need - everyday.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.